spacer
home > ict > winter 2020 > security, compliance, and control
PUBLICATIONS
International Clinical Trials

Security, Compliance, and Control




The whole pharmaceutical world is built upon a foundation of intellectual property (IP) and personally identifiable information. Without the masses of data collected from clinical trials, groundbreaking drug formulas, and research, it is easy to see how some of the top global pharma organisations would no longer be at the top of the game, highlighting just how valuable all this information is.

In 2018, the pharma industry was estimated at an astonishing $1.11 trillion, with this set to rise to $1.43 trillion by 2020. While regulatory compliance is no new thing for pharma companies, the introduction of the EU GDPR back in May 2018 means that any organisation found to be in breach of EU citizens’ data could be fined up to €20 million, or 4% of their global turnover. For a pharma company with a turnover of $30 billion, this could be a fine of $1.2 billion, which would blow the current GDPR record fine (€50 million for Google) out of the water.

As with anything, the monetary loss of a data breach is just the tip of the iceberg. Following a fine for a breach of regulatory compliance is a hugely damaged reputation and a very valuable potential loss of revenue-making IP and trade secrets.



Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
About the author


Georgina Stockley is the Marketing Communications Manager at Boldon James, whose experience is in the financial services and technology sectors. Having seen first-hand the damage that can be caused by a lack of proper data protection within an organisation, Georgina is passionate about helping others understand how implementing simple solutions can have the biggest impact on their businesses.
Print this page
Send to a friend
Privacy statement
News and Press Releases

Cerba Research and ACT Genomics Announce Strategic Joint Venture — CerbACT Asia

This expansion of the precision medicine offering includes central labs, flow cytometry, histopathology, and translational science laboratory services. Deep scientific expertise from both sides of this strategic alliance will support new growth areas for biotech and pharma clients globally and drive better patient outcomes across all phases of clinical trials.
More info >>

White Papers

Microalgae Culture Using the DASGIP® PBR4 Module for Illumination with a New Brunswick™ CelliGen® 310 Stirred-tank Bioreactor

Eppendorf

The number of bioprocess applications for microalgae has increased in recent years, particularly in the fi eld of biofuel production. The combination of the New Brunswick CelliGen 310 stirred-tank bioreactor and the DASGIP LED Illumination System creates a bioreactor setup which is capable of supporting high density microalgal growth. Using the stand-alone Eppendorf DASGIP PBR4 Module, LED illumination spectra and intensities can be controlled for optimal support of all types of chlorophylls and carotenoids. For this study in which high density culture of up to 1.5 x 107 cells/mL was achieved, the unicellular freshwater alga, Dunaliella tertiolecta, was used.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement